Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onyx BiotecNSE:ONYX +4.89%13 Return-on-Tangible-Asset is 1.47% as of Mar. 2026, which is 73% below its 10-year median of 5.47. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Onyx Biotec ranks worse than 52.05% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Onyx Biotec's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹13.7 Mil. Onyx Biotec's average total tangible assets for the quarter that ended in Mar. 2026 was ₹936.4 Mil. Therefore, Onyx Biotec's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 1.47%.
The historical rank and industry rank for Onyx Biotec's Return-on-Tangible-Asset or its related term are showing as below:
NSE:ONYX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -0.23 Med: 5.47 Max: 9.1
Current: -0.23
During the past 5 years, Onyx Biotec's highest Return-on-Tangible-Asset was 9.10%. The lowest was -0.23%. And the median was 5.47%.
NSE:ONYX's Return-on-Tangible-Asset is ranked worse than 52.05% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs NSE:ONYX: -0.23
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Onyx Biotec Return-on-Tangible-Asset Related Terms
Onyx Biotec Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Onyx Biotec's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONYX vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Onyx Biotec's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Biotec Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Onyx Biotec's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.47% mean?
Onyx Biotec (NSE:ONYX) has a Return-on-Tangible-Asset of 1.47% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Onyx Biotec and its competitors. This is 73% below median its historical median of 5.47. According to the industry distribution chart, Onyx Biotec ranks #445 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 52%.
Is Onyx Biotec's Return-on-Tangible-Asset too high?
Onyx Biotec's current Return-on-Tangible-Asset of 1.47% is 73% below median its 10-year median of 5.47. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.56. Onyx Biotec's value of 1.47% is 162.5% above this industry median. Based on the distribution chart, Onyx Biotec ranks #445 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Onyx Biotec ranks #445 out of 855 companies for Return-on-Tangible-Asset. This places Onyx Biotec in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.56. Onyx Biotec's value of 1.47% is 162.5% above this benchmark. While the company's 10-year median is 5.47 vs. the industry median of 0.56, Onyx Biotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.56, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Biotec's current Return-on-Tangible-Asset of 1.47% is 162.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Onyx Biotec and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Biotec's current Return-on-Tangible-Asset is 1.47%, which is 73% below median its own 10-year median of 5.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current Return-on-Tangible-Asset of 1.47%. The current Return-on-Tangible-Asset is 1.47%, which is 73% below median its 10-year median of 5.47 and 162.5% above the Medical Devices & Instruments industry median of 0.56. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current Return-on-Tangible-Asset is 1.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score
Get the complete analysis for NSE:ONYX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONYX has been successfully added to your 
